CR20230256A - Compuestos farmacéuticos - Google Patents

Compuestos farmacéuticos

Info

Publication number
CR20230256A
CR20230256A CR20230256A CR20230256A CR20230256A CR 20230256 A CR20230256 A CR 20230256A CR 20230256 A CR20230256 A CR 20230256A CR 20230256 A CR20230256 A CR 20230256A CR 20230256 A CR20230256 A CR 20230256A
Authority
CR
Costa Rica
Prior art keywords
compounds
pharmaceutical compounds
muscarinic
agonists
receptors
Prior art date
Application number
CR20230256A
Other languages
English (en)
Inventor
Charlotte Fieldhouse
Miles Stuart Congreve
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Publication of CR20230256A publication Critical patent/CR20230256A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invención se refiere a compuestos que son agonistas del receptor muscarínico M<sub>1</sub> y M<sub>4</sub> y que son útiles en el tratamiento de enfermedades mediadas por los receptores muscarínicos M<sub>1 </sub>y/o M<sub>4</sub>. También se proporcionan composiciones farmacéuticas que contienen los compuestos y los usos terapéuticos de los compuestos. Los compuestos proporcionados son de fórmula (1): y sus sales.
CR20230256A 2020-12-18 2021-12-20 Compuestos farmacéuticos CR20230256A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2020191.9A GB202020191D0 (en) 2020-12-18 2020-12-18 Pharmaceutical compounds
PCT/GB2021/053372 WO2022129951A1 (en) 2020-12-18 2021-12-20 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
CR20230256A true CR20230256A (es) 2023-09-29

Family

ID=74221349

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230256A CR20230256A (es) 2020-12-18 2021-12-20 Compuestos farmacéuticos

Country Status (17)

Country Link
US (1) US11999745B2 (es)
EP (1) EP4263536A1 (es)
JP (1) JP2024504252A (es)
KR (1) KR20230121830A (es)
CN (1) CN116848109A (es)
AU (1) AU2021404194A1 (es)
CA (1) CA3202054A1 (es)
CL (1) CL2023001755A1 (es)
CO (1) CO2023007838A2 (es)
CR (1) CR20230256A (es)
DO (1) DOP2023000125A (es)
EC (1) ECSP23044370A (es)
GB (1) GB202020191D0 (es)
IL (1) IL303484A (es)
MX (1) MX2023007140A (es)
PE (1) PE20240646A1 (es)
WO (1) WO2022129951A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014012056B1 (pt) 2011-11-18 2021-12-14 Heptares Therapeutics Limited Compostos agonistas do receptor m1 muscarínico, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para tratar um distúrbio cognitivo ou psicótico ou para tratamento ou diminuição da severidade da dor aguda, crônica, neuropática ou inflamatória
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56110674A (en) 1980-01-24 1981-09-01 Janssen Pharmaceutica Nv Novel 11*cyclohexyl**44aryll44piperidine carboxylic acid derivative
US4369184A (en) 1980-01-24 1983-01-18 Janssen Pharmaceutica N.V. 1-(Cyclohexyl)-4-aryl-4-piperidinecarboxylic acid derivatives
US5852029A (en) 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
GB9300194D0 (en) 1993-01-06 1993-03-03 Wyeth John & Brother Ltd Piperazine derivatives
US5446051A (en) 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
EP0786997A4 (en) 1994-10-27 1998-03-11 Merck & Co Inc MUSCARINE ANAGONISTS
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
WO1997016187A1 (en) 1995-10-31 1997-05-09 Merck & Co., Inc. Muscarine antagonists
US5854245A (en) 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
US6664258B1 (en) 1996-08-26 2003-12-16 Pfizer Inc Spirocyclic dopamine receptor subtype ligands
AU734892B2 (en) 1997-06-18 2001-06-28 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
GB9715892D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic compounds
WO1999032486A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
WO1999032489A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
WO1999032479A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Phthalimide-piperidine, -pyrrolidine and -azepine derivatives, their preparation and their use as muscarinic receptor (ant-)agonists
AU2307999A (en) 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
CZ286152B6 (cs) 1998-03-13 2000-01-12 Miroslav Ing. Csc. Vlček Transparentní a semitransparentní difrakční prvky
ATE289516T1 (de) 1999-05-04 2005-03-15 Schering Corp Pegyliertes interferon alpha in kombination mit einem ccr5 antagonisten für eine hiv therapie
CN1524527A (zh) 1999-05-04 2004-09-01 ���鹫˾ 用作ccr5拮抗剂的哌啶衍生物
US6387930B1 (en) 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
JP2003529546A (ja) 1999-09-13 2003-10-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド システインプロテアーゼの可逆的インヒビターとして有益な新規スピロ複素環化合物
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
DE60013464T2 (de) 1999-10-13 2005-09-15 Banyu Pharmaceutical Co., Ltd. Substituierte imidazolin-derivate
EP1379506A2 (en) 2000-11-28 2004-01-14 Eli Lilly And Company Substituted carboxamides
EP1386920A4 (en) 2001-04-20 2005-09-14 Banyu Pharma Co Ltd DERIVATIVES OF BENZIMIDAZOLONE
EP1395257A1 (en) 2001-06-12 2004-03-10 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
WO2004089942A2 (en) 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
GB0128378D0 (en) 2001-11-27 2002-01-16 Smithkline Beecham Plc Novel Compounds
US7550459B2 (en) 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
JP4509565B2 (ja) 2001-12-28 2010-07-21 アカディア ファーマシューティカルズ，インコーポレーテッド ムスカリン作動薬としてのテトラヒドロキノリン類似体
US7256186B2 (en) 2002-02-06 2007-08-14 Schering Corporation Gamma secretase inhibitors
US20040171614A1 (en) 2002-02-06 2004-09-02 Schering-Plough Corporation Novel gamma secretase inhibitors
WO2003082847A1 (fr) 2002-03-28 2003-10-09 Tanabe Seiyaku Co., Ltd. Derive de benzofurane
EP1552842A1 (en) 2002-06-07 2005-07-13 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives
DE60226906D1 (de) 2002-07-31 2008-07-10 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo ä3.1.0ühexanderivate, die sich als muscarinrezeptorantagonisten eignen
SI1551835T1 (sl) 2002-09-30 2007-06-30 Neurosearch As Novi 1,4-diazabicikloalkanski derivati, njihova priprava in uporaba
CN1753897A (zh) 2002-11-22 2006-03-29 日本烟草产业株式会社 稠合双环含氮杂环
JP4828829B2 (ja) 2002-11-27 2011-11-30 インサイト・コーポレイション ケモカイン受容体のモジュレーターとしての３−アミノピロリジン誘導体
JPWO2004069828A1 (ja) 2003-02-04 2006-05-25 三菱ウェルファーマ株式会社 ピペリジン化合物およびその医薬用途
CA2529686C (en) 2003-07-17 2010-06-15 Astellas Pharma Inc. 2-acylaminothiazole derivative or salt thereof
US20070078120A1 (en) 2003-10-21 2007-04-05 Hitoshi Ban Novel piperidine derivative
CA2554465A1 (en) 2004-02-05 2005-08-25 Schering Corporation Piperidine derivatives useful as ccr3 antagonists
WO2005075484A2 (en) 2004-02-10 2005-08-18 F. Hoffmann-La Roche Ag Chemokine ccr5 receptor modulators
US7488745B2 (en) 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
US7504424B2 (en) 2004-07-16 2009-03-17 Schering Corporation Compounds for the treatment of inflammatory disorders
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
US7880007B2 (en) 2004-11-29 2011-02-01 Vertex Pharmaceuticals Incorporated Bicyclic substituted phenyl piperidine modulators of muscarinic receptors
JP4774995B2 (ja) 2005-01-12 2011-09-21 アステラス製薬株式会社 アシルアミノチアゾール誘導体を有効成分とする医薬組成物
WO2006105035A2 (en) 2005-03-28 2006-10-05 Vertex Pharmaceuticals Incorporated Muscarinic modulators
US8329694B2 (en) 2005-06-24 2012-12-11 Toyama Chemical Co., Ltd. Quinoxalinones as antibacterial composition
AU2006330866A1 (en) 2005-12-22 2007-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
CA2635231C (en) 2005-12-29 2014-07-15 Abbott Laboratories Protein kinase inhibitors
KR20080098070A (ko) 2006-02-22 2008-11-06 버텍스 파마슈티칼스 인코포레이티드 무스카린성 수용체의 조절제로서의 스피로 축합된 피페리딘
JP2009527568A (ja) 2006-02-22 2009-07-30 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体の調節剤
WO2008021375A2 (en) 2006-08-15 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
CN101610761A (zh) 2006-12-22 2009-12-23 诺瓦提斯公司 作为ddp-iv抑制剂的1-氨基甲基-l-苯基-环己烷衍生物
WO2008117229A1 (en) 2007-03-23 2008-10-02 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
JP5564033B2 (ja) 2008-03-27 2014-07-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼの新規インヒビターとしてのアザ−ビシクロヘキシル置換インドリルアルキルアミノ誘導体
CA2741709A1 (en) 2008-10-29 2010-05-06 Gruenenthal Gmbh Substituted spiroamines
EA020548B1 (ru) 2008-12-19 2014-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Циклические пиримидин-4-карбоксамиды в качестве антагонистов рецептора ccr2, предназначенные для лечения воспаления, астмы и хозл
CA2758934A1 (en) 2009-04-17 2010-10-21 Janssen Pharmaceutica Nv 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2
FR2945531A1 (fr) 2009-05-12 2010-11-19 Sanofi Aventis Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique
US20130197027A1 (en) 2010-03-10 2013-08-01 Craig Lindsley Heterocyclyl-azabicyclo[3.2.1]octane analogs as selective m1 agonists and methods of making and using same
US8822447B2 (en) 2010-04-22 2014-09-02 Janssen Pharmaceutica Nv Indazole compounds useful as ketohexokinase inhibitors
EP2563127A4 (en) 2010-04-27 2013-11-06 Merck Sharp & Dohme PROLYLCARBOXYPEPTIDASE INHIBITORS
EP2568812B1 (en) 2010-05-11 2016-10-26 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
US20130064770A1 (en) 2010-05-28 2013-03-14 Ge Healthcare Limited Radiolabeled compounds and methods thereof
US20130184257A1 (en) 2010-09-17 2013-07-18 Thomas Daniel Aicher Piperidinyl-substituted lactams as gpr119 modulators
EP2685828A4 (en) 2011-03-17 2014-08-13 Merck Sharp & Dohme SUBSTITUTED 3-AZABICYCLO [3,1,0-] HEXAN DERIVATIVES AS CCR2 ANTAGONISTS
JP2013010719A (ja) 2011-06-30 2013-01-17 Dainippon Sumitomo Pharma Co Ltd ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途
BR112014012056B1 (pt) 2011-11-18 2021-12-14 Heptares Therapeutics Limited Compostos agonistas do receptor m1 muscarínico, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para tratar um distúrbio cognitivo ou psicótico ou para tratamento ou diminuição da severidade da dor aguda, crônica, neuropática ou inflamatória
ES2602039T3 (es) 2012-09-18 2017-02-17 Heptares Therapeutics Limited Compuestos aza bicíclicos como agonistas del receptor M1 muscarínico
WO2014122474A1 (en) 2013-02-07 2014-08-14 Takeda Pharmaceutical Company Limited Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists
EP3406609B1 (en) 2014-02-06 2024-06-26 Nxera Pharma UK Limited Bicyclic aza compounds as muscarinic receptor agonists
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
SI3265459T1 (sl) 2015-02-13 2019-09-30 Suven Life Sciences Limited, Amidne spojine kot 5-HT4 receptor agonisti
GB201504675D0 (en) 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513740D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201513742D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
US10259787B2 (en) 2016-10-14 2019-04-16 Heptares Therapeutics Limited Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
GB201709652D0 (en) * 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
TW201922758A (zh) 2017-10-24 2019-06-16 美商歐樂根公司 烯胺及烯胺的非鏡像選擇性還原
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201810245D0 (en) * 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202103211D0 (en) 2021-03-08 2021-04-21 Heptares Therapeutics Ltd Pharmaceutical compounds for use in therapy

Also Published As

Publication number Publication date
CL2023001755A1 (es) 2024-01-05
ECSP23044370A (es) 2023-08-31
US11999745B2 (en) 2024-06-04
AU2021404194A1 (en) 2023-08-03
EP4263536A1 (en) 2023-10-25
DOP2023000125A (es) 2023-08-31
JP2024504252A (ja) 2024-01-31
MX2023007140A (es) 2023-08-25
KR20230121830A (ko) 2023-08-21
CO2023007838A2 (es) 2023-10-30
CN116848109A (zh) 2023-10-03
US20220380379A1 (en) 2022-12-01
CA3202054A1 (en) 2022-06-23
IL303484A (en) 2023-08-01
WO2022129951A1 (en) 2022-06-23
GB202020191D0 (en) 2021-02-03
PE20240646A1 (es) 2024-04-04

Similar Documents

Publication Publication Date Title
MX2023007140A (es) Compuestos farmaceuticos.
MX2020014156A (es) Oxadiazoles como agonistas de los receptores muscarinicos m1 y/o m4.
PH12021550166A1 (en) Nlrp3 inflammasome inhibitors
IN2014KN01075A (es)
ATE453636T1 (de) Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren
HK1154587A1 (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
TN2012000231A1 (en) Quinoline amide m1 receptor positive allosteric modulators
MX2009012579A (es) Antagonistas piridil piperidina del receptor de orexina.
CR20220105A (es) Degradadores bifuncionales de brd9 y sus métodos de uso
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
EP2037739A4 (en) POSITIVE ALLOSTERIC EFFECTORS OF BENZYL-SUBSTITUTED QUINOLONE M1 RECEPTOR
MX2020011405A (es) Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos.
MX2012002583A (es) Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1.
MX2023011377A (es) Derivados de ciclobutilo 1,3-sustituidos y sus usos.
ATE552257T1 (de) Positive allosterische chinolizidinon-m1- rezeptormodulatoren
MX2021003508A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
MX2021008510A (es) Derivados de tiazolopiridina como antagonistas del receptor de adenosina.
MX2012007005A (es) Tiazoles biciclicos como moduladores alostericos de recptores de glutamato metabotropico subtipo 5.
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu&#39;antagonistes des récepteurs des orexines
ZA202306305B (en) Pharmaceutical compounds
WO2024028458A3 (en) Crystalline forms and salts of a muscarinic receptor agonist
MX2022001516A (es) Antagonistas del receptor de neuropeptido ff.
MX2021014941A (es) Inhibidores de dopamina-b-hidroxilasa.